Sensorium Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for brain and mental health conditions. Utilizing its proprietary SensAI platform, the company integrates artificial intelligence, chemistry, and neuroscience to explore and decode the complexities of human biology. The company’s lead product, SENS-01, a first-in-class treatment for anxiety, has received IND clearance from the FDA to enter Phase 1 clinical trials. With a commitment to advancing mental health through re-engineering naturally co-evolved molecules, Sensorium aims to overcome the limitations of existing treatments, enhancing patient outcomes through a holistic and precise approach.